Whitehawk Therapeutics (WHWK) announced the appointment of Margaret Dugan, MD, as Chief Medical Officer, CMO. Dr. Dugan brings more than 30 years of global oncology drug development experience, with extensive expertise in early-stage clinical development and regulatory strategy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WHWK:
- Whitehawk Therapeutics Reports Q3 2025 Financial Results
- Cautious Optimism for Whitehawk Therapeutics: Balancing Innovation with Risk in Next-Gen ADCs
- Cautious Outlook on Whitehawk Therapeutics Amid Financial Challenges and Clinical Uncertainties
- Whitehawk Therapeutics reports Q3 EPS (26c) vs. (46c) last year
- Tempus AI enters pact with Whitehawk Therapeutics to advance oncology research